Normal Population
Conditions
Keywords
beer
Brief summary
Beneficial effects of moderate chronic consumption of beer have been extensively reported, however, the mechanisms have not been elucidated yet. Gut microbiota is an important mediator in the homeostasis of the host. Polyphenols act as bacterial substrates and modulators of the gut microbiota. Indeed, the investigators have previously observed that the chronic moderate consumption of red wine by metabolic syndrome patients triggered in an amelioration of the metabolic syndrome variables, and this effect was mediated, at least partially, by the interaction of the gut microbiota with the polyphenols of the red wine. In this manner, beer has a medium content of polyphenols. Thus, the investigators propose that the beneficial effects of moderate chronic consumption of beer could be because of the action of the gut microbiota with the beer polyphenols. The investigators are going to perform an intervention study in which normal volunteers will consume three different beer types with different content in polyphenols and it will be analyzed the gut microbiota profile (Metagenomics), metabolites (Metabolomics) and metabolic syndrome markers (gene expression, ELISA) to establish the correspondent relationships, trying to decipher the implication of the gut microbiota in the beneficial effects of moderate chronic consumption of beer.
Interventions
DIETARY_SUPPLEMENTBeer
A daily beer will be consumed by the participants during a total of 6 weeks, changing every 2 weeks from alcohol-free lager beer, lager beer and dark beer
Sponsors
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Age \> 18 years * Usual consumer of Beer
Exclusion criteria
* being a non usual beer-consumer, * body mass index (BMI) \> 40 kg m2. * acute or chronic infection, inflammatory disease or endocrine disorders; history of cancer; leukocytosis; anti-inflammatory, corticosteroid or hormone treatment. * history of alcohol abuse or drug dependence. * under a restrictive diet or a weight change ≥5 kg during the 3 months prior to the study. * antibiotic therapy, prebiotics, probiotics, synbiotics, vitamin supplements or any other medical treatment influencing intestinal microbiota during the 3 months before the start of the study or during the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in gut microbiota | Baseline, 2nd, 4th and 6th weeks visits | change from baseline in 16S rRNA amplicons determined in DNA from feces after 6 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in waist circumference | Baseline and 6th weeks visits | Change from baseline in waist circumference (cm) after the completion of the trial |
| Change in glucose concentration | Baseline and 6th weeks visits | Change from baseline in serum glucose level after the completion of the trial |
| Change in caloric consumption | Baseline and 6th weeks visits | change from baseline in the number of caloric consumption measured by an structured nutrient intake |
| Change in triglycerides concentration | Baseline and 6th weeks visits | Change from baseline in serum triglycerides level after the completion of the trial |
| Change in blood pressure | Baseline and 6th weeks visits | Change from baseline in blood pressure (systolic and diastolic) after the completion of the trial |
| Change in HDL-cholesterol concentration | Baseline and 6th weeks visits | Change from baseline in serum HDL-cholesterol level after the completion of the trial |
Countries
Spain
Outcome results
None listed